AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|
26.7 C
New York
Friday, September 11, 2026

Tag: investors

newssourceFORcompanyinformationcontent1releasesmarket

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Casino Group Communication

Casino Group communication

BW IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

MemeToro Price Prediction: $1 Talk Returns as Presale Buyers Bet on MemeToro AI Agent Solutions

ZURICH, June 07, 2026 (GLOBE NEWSWIRE) -- The cryptocurrency market is witnessing a massive convergence of artificial intelligence and digital culture. Investors are shifting capital toward functional crypto ecosystems. Memecoins have evolved far beyond basic internet jokes.

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers